Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Free Cash Flow (2023 - 2025)

Historic Free Cash Flow for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to -$39.0 million.

  • CG Oncology's Free Cash Flow fell 14494.91% to -$39.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$117.1 million, marking a year-over-year decrease of 6106.49%. This contributed to the annual value of -$78.9 million for FY2024, which is 7283.0% down from last year.
  • Latest data reveals that CG Oncology reported Free Cash Flow of -$39.0 million as of Q3 2025, which was down 14494.91% from -$28.0 million recorded in Q2 2025.
  • Over the past 5 years, CG Oncology's Free Cash Flow peaked at -$8.0 million during Q1 2023, and registered a low of -$39.0 million during Q3 2025.
  • Moreover, its 3-year median value for Free Cash Flow was -$16.1 million (2024), whereas its average is -$20.1 million.
  • In the last 5 years, CG Oncology's Free Cash Flow plummeted by 22587.03% in 2024 and then tumbled by 1264.99% in 2025.
  • Quarter analysis of 3 years shows CG Oncology's Free Cash Flow stood at -$14.6 million in 2023, then crashed by 42.51% to -$20.9 million in 2024, then crashed by 86.82% to -$39.0 million in 2025.
  • Its Free Cash Flow stands at -$39.0 million for Q3 2025, versus -$28.0 million for Q2 2025 and -$29.3 million for Q1 2025.